SALT LAKE CITY and AMSTERDAM, June 1,
2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX:
PHIA) and Navican, an Intermountain Healthcare company, today
signed an agreement to deploy a precision health informatics
solution that will allow hospitals and health systems worldwide to
access the sophisticated services of Intermountain's successful
precision medicine program in a "turn-key" manner. The new
services, that will be made available through Navican, are aimed at
improving outcomes for late stage cancer patients and will offer
specialized programs with expert guidance for both oncologists and
patients.
The new solution will leverage Navican's TheraMap Precision
Cancer Care™ services and Philips IntelliSpace
Genomics platform that integrates large-scale genomic analysis with
extensive contextual clinical patient data and that is built to
implement precision medicine programs at the point of care. The
Philips platform seamlessly integrates Illumina's next-generation
sequencing technologies.
"Despite major technological advances in tumor sequencing
capabilities and laboratories, gaps remain between these advanced
diagnostics and actually getting patients onto the appropriate
therapeutic paths," says Lincoln
Nadauld, MD, PhD, executive director of Intermountain
Precision Genomics. "Through this joint approach we are bringing
together the latest technologies with the aim to provide community
hospitals and treatment centers worldwide with the opportunity to
implement Intermountain's best practice in precision medicine into
their everyday care practices."
Nationally leading precision cancer genomics
program
Intermountain Healthcare - a Utah-based, Integrated Delivery Network
comprising of 22 hospitals and 185 clinics – provides a nationally
leading precision cancer genomics program through its Intermountain
Precision Genomics laboratory. The genetic makeup of each patient's
cancer is analyzed. Then a team of skilled molecular tumor
specialists and specialized treatment navigators is employed to
review each test and determine how to most effectively treat that
cancer case. This team approach gives oncologists the information
and support they need to prepare a customized, targeted treatment
plan for each patient. Nearly 80% of the patients treated at
Intermountain Precision Genomics have been connected to targeted
drug therapies, which can help lengthen survival in advanced cancer
patients without increasing costs.
"Through Navican this approach and all services, including
continuous remote access to Intermountain's tumor specialists and
treatment navigators, are offered to community hospitals,
independent hospital networks and other Integrated Delivery
Networks," says Ingo Chakravarty,
CEO of Navican. "Patients are based in the community, across
the United States and around the
world, so should precision medicine, being accessible to all, not
just a few."
To this end, Navican will use Philips IntelliSpace Genomics, a
comprehensive precision medicine platform built to support the
implementation and scaling of informatics-heavy precision medicine
programs. Resulting from more than a decade of research and
development with clinical partners, it offers integrated workflows
with advanced analytic capabilities and clinical decision support
by unifying the whole patient picture, and streamlines
collaboration across hospitals to support pathologists,
oncologists, and researchers. The platform integrates N-of-One's
interpretation capabilities and extensive knowledge-bases providing
ready access to a vast amount of available reference literature,
guidelines, and evidence further enhancing the platform's clinical
trial matching tools.
"Together with Navican we aim to provide a seamless end-to-end
solution using the latest technologies available," says
Louis Culot, General Manager Philips
Genomics. "Hospitals and health systems will be able to send their
patient samples to Navican, for advanced molecular analysis,
interpretation and guidance by Intermountain. At the same time they
will have access to Intermountain's advanced services while genome
informatics and data flow are fully implemented through Philips
IntelliSpace Genomics, and can be further integrated with local EMR
and lab systems."
The "turnkey" precision medicine solution will first be made
available within the Intermountain Healthcare network. Availability
to other hospitals and healthcare systems worldwide is expected
second half of 2017. The solution will be presented at Philips
booth #5107 and Intermountain' s booth #3123 at the American
Society of Clinical Oncology Annual Meeting (ASCO) taking place 2 –
6 June in Chicago U.S.
More information:
Joost Maltha
Philips Group Press Office
Tel.: +31 6 10 55 8116
E-mail: Joost.Maltha@philips.com
Twitter: @JoostMaltha
Daron
Cowley
Intermountain Healthcare
Tel.: +1-801-442-2834
E-mail: daron.cowley@imail.org
Twitter: @intermountain
About Royal
Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a
leading health technology company focused on improving people's
health and enabling better outcomes across the health continuum
from healthy living and prevention, to diagnosis, treatment and
home care. Philips leverages advanced technology and deep clinical
and consumer insights to deliver integrated solutions.
Headquartered in the Netherlands,
the company is a leader in diagnostic imaging, image-guided
therapy, patient monitoring and health informatics, as well as in
consumer health and home care. Philips' health technology portfolio
generated 2016 sales of EUR 17.4
billion and employs approximately 70,000 employees with
sales and services in more than 100 countries. News about Philips
can be found at www.philips.com/newscenter.
About Navican
NAVICAN, an Intermountain Healthcare
company, offers Precision Cancer Care™ to transform
and advance cancer care for patients everywhere that advanced
therapies are available. Navican offers expert therapy
recommendations and experienced navigators to help patients and
their caregivers get the precision therapy they need as soon as
possible. Navican uses TheraMap™, a comprehensive
end-to-end service to help oncologists and patients harness the
power of precision medicine to improve outcomes and reduce cost.
Developed through years of experience and clinical best practices
of Intermountain Healthcare, TheraMap™ combines
state-of-the-art next generation sequencing technology, clinical
expertise and a molecular tumor board to provide a treatment
recommendation. For more information, please visit us at
www.navican.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-and-illumina-team-up-with-navican-an-intermountain-healthcare-company-to-accelerate-the-delivery-of-precision-medicine-to-health-systems-worldwide-300466840.html
SOURCE Royal Philips